US 12,280,057 B2
Vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing
Hunter Moyer, Rapid City, SD (US); and Daniel Heglund, Rapid City, SD (US)
Assigned to SOUTH DAKOTA BOARD OF REGENTS, Pierre, SD (US)
Filed by SOUTH DAKOTA BOARD OF REGENTS, Pierre, SD (US)
Filed on Sep. 8, 2021, as Appl. No. 17/447,101.
Application 17/447,101 is a continuation of application No. PCT/US2020/021697, filed on Mar. 9, 2020.
Claims priority of provisional application 62/815,616, filed on Mar. 8, 2019.
Prior Publication US 2021/0393639 A1, Dec. 23, 2021
Int. Cl. A61K 31/522 (2006.01); A61K 31/21 (2006.01); A61K 31/5415 (2006.01); A61K 31/655 (2006.01); A61K 33/06 (2006.01); A61K 47/44 (2017.01); A61P 7/08 (2006.01); A61P 9/08 (2006.01)
CPC A61K 31/522 (2013.01) [A61K 31/5415 (2013.01); A61K 31/655 (2013.01); A61K 33/06 (2013.01); A61K 47/44 (2013.01); A61P 7/08 (2018.01)] 20 Claims
 
1. A vasoactive composition for improving tissue perfusion comprising:
from about 10 wt. % to about 30 wt. % of a phosphodiesterase inhibitor;
from about 5 wt. % to about 35 wt. % of a calcium channel blocker, wherein the calcium channel blocker is magnesium sulfate;
from about 0.1 wt. % to about 30 wt. % of a nitric oxide producer;
from about 0.1 wt. % to about 30 wt. % of an α-adrenergic antagonist; and
from about 15 wt. % to about 75 wt. % of a carrier.